Form 4: Akero Therapeutics Senior VP Exercises Stock Options and Sells Shares Under Pre-Arranged 10b5-1 Plan

Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, executed a pre-planned transaction on June 2, 2025, involving the exercise of stock options and the subsequent sale of an equivalent number of shares.

Summary

• Patrick Lamy, Senior VP, Commercial Strategy, of Akero Therapeutics, Inc. (AKRO), engaged in a series of transactions on June 2, 2025.
• Mr. Lamy exercised stock options to acquire 4,000 shares of Common Stock at an exercise price of $19.87 per share.
• Concurrently, he sold a total of 4,000 shares of Common Stock in multiple transactions.
• The sales included 600 shares at a weighted-average price of $49.398 (ranging from $48.85 to $49.83), 3,300 shares at a weighted-average price of $50.459 (ranging from $49.85 to $50.78), and 100 shares at a price of $51.04.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted on January 6, 2025.
• Following these transactions, Mr. Lamy directly beneficially owns 33,492 shares of Common Stock and 66,182 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's an exercise-and-sell transaction under a pre-arranged 10b5-1 plan, which is a common and expected practice for executives monetizing vested equity compensation, rather than indicating a negative outlook on the company.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and non-opportunistic sale, which can be viewed favorably by the market.
• The exercise of options at $19.87 and subsequent sale at significantly higher prices (ranging from $49.398 to $51.04) demonstrates a substantial profit for the insider on these specific shares.

Negatives

• The sale of shares by an insider, even if pre-planned, represents a reduction in their direct equity holdings, which some investors might interpret as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing details past insider transactions and does not provide any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of insider trading activity, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape beyond the company's stock performance at the time of the transaction.

Stakeholder Impact

• Shareholders may note the monetization of vested equity by a senior executive, which is a common practice and generally not considered a significant indicator of future company performance when executed under a 10b5-1 plan.

Key Dates

Recommendation

Keywords

Akero Therapeutics, AKRO, Form 4, insider trading, stock options, 10b5-1 plan, executive compensation, share sale